Crucell, J&J in influenza deal

Crucell N.V. (Euronext:CRXL; NASDAQ:CRXL) and Johnson & Johnson (NYSE:JNJ) partnered to discover, develop and commercialize mAbs and vaccines to treat and prevent influenza and other infectious and non-infectious diseases. J&J made an equity investment of EUR 301.8 million ($440.8 million) in Crucell though the purchase of 14.6 million shares at EUR 20.63, giving J&J an 18% stake in Crucell. The deal price is a 29% premium to Crucell's close of EUR 15.95 on Friday, the last trading day before the deal was announced. Crucell is eligible for milestones of "hundreds of millions of euros" and royalties. ...